About quoin pharmaceuticals - QNRX
Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. Its product pipeline includes QRX003, QRX004, QRX007, and QRX008. The company was founded by Michael Myers and Denise Carter on March 5, 2018 and is headquartered in Ashburn, VA.
QNRX At a Glance
Quoin Pharmaceuticals Ltd.
42127 Pleasant Forest Court
Ashburn, Virginia 20148-7349
| Phone | 1-703-980-4182 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -15,930,033.05 | |
| Sector | Health Technology | Employees | 4 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
QNRX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 1.648 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.176 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
QNRX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -3,982,508.263 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
QNRX Liquidity
| Current Ratio | 3.607 |
| Quick Ratio | 3.607 |
| Cash Ratio | 3.379 |
QNRX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -88.256 |
| Return on Equity | -142.714 |
| Return on Total Capital | -121.421 |
| Return on Invested Capital | -142.714 |
QNRX Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |